US needs to invest more in new technology for diabetes care
This article was originally published in Clinica
Executive Summary
The US allocated $1.32bn to medical expenditure and lost productivity in 2001 compared, to $98bn in 1997, according to a new study by the American Diabetes Association (ADA). The direct medical costs of diabetes more than doubled during the same period, from $44bn in 1997 to $91.8bn in 2002, the group said. Greater preparedness to use new technologies would result in lower healthcare costs and better productivity, believes the ADA.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.